FORM 3
        	UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
	OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5	
                      	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	                      	

1. Name and Address of Reporting Person *

Wagner Paul A.	2. Date of Event Requiring Statement (MM/DD/YYYY)
6/15/2020 
	3. Issuer Name and Ticker or Trading Symbol

Forte Biosciences, Inc. [FBRX]	
(Last)       (First)       (Middle)

C/O FORTE BIOSCIENCES, INC., 1124 W. CARSON STREET, MRL BLDG. 3-320	4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
See Remarks /	
(Street)

TORRANCE, CA 90502      

(City)             (State)             (Zip)	5. If Amendment, Date Original Filed(MM/DD/YYYY)
 
	6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person	

Table I - Non-Derivative Securities Beneficially Owned	
1.Title of Security
(Instr. 4)	2. Amount of Securities Beneficially Owned
(Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)	4. Nature of Indirect Beneficial Ownership
(Instr. 5)	
Common Stock 	2272049 	D 	 	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)	
1. Title of Derivate Security
(Instr. 4)	2. Date Exercisable and Expiration Date
(MM/DD/YYYY)	3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)	6. Nature of Indirect Beneficial Ownership
(Instr. 5)	
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy) 	 (1)	12/19/2028 	Common Stock 	421653 	$0.86 	D 	 	

Explanation of Responses:	
(1) 	Subject to the Reporting Person continuing to be a Service Provider (as defined in the Forte Subsidiary, Inc. 2018 Equity Incentive Plan) through each applicable vesting date, 210,826 of the shares subject to the option shall vest upon the start of a Phase 2b/3 trial for the Issuer's lead product candidate and 210,827 of the shares subject to the option shall vest upon completion of a Phase 2b/3 trial for the Issuer's lead product candidate.	

Remarks:
CEO, President, Secretary and Chair of the Board

Exhibit 24 - Power of Attorney	

Reporting Owners	
Reporting Owner Name / Address	Relationships	
	Director	10% Owner	Officer	Other	
Wagner Paul A.
C/O FORTE BIOSCIENCES, INC.
1124 W. CARSON STREET, MRL BLDG. 3-320
TORRANCE, CA 90502	X		See Remarks		

Signatures		
/s/ Paul A. Wagner, Ph.D		6/17/2020	
**Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.	
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).	
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).	
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.	
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.	

                                                                      Exhibit 24

                               POWER OF ATTORNEY

        The undersigned, as a Section 16 reporting person of Forte Biosciences,
Inc. (the "Company"), hereby constitutes and appoints Antony Riley, Daniel
Koeppen, Benjamin Capps and Thomas Hornish the undersigned's true and lawful
attorneys-in-fact to:

        1.    complete and execute Forms 3, 4 and 5 and other forms and all
              amendments thereto as such attorneys-in-fact shall in their
              discretion determine to be required or advisable pursuant to
              Section 16 of the Securities Exchange Act of 1934 (as amended) and
              the rules and regulations promulgated thereunder, or any successor
              laws and regulations, as a consequence of the undersigned's
              ownership, acquisition or disposition of securities of the
              Company; and

        2.    do all acts necessary in order to file such forms with the
              Securities and Exchange Commission, any securities exchange or
              national association, the Company and such other person or agency
              as the attorneys-in-fact shall deem appropriate.

        The undersigned hereby ratifies and confirms all that said attorneys-in-
fact and agent shall do or cause to be done by virtue hereof.  The undersigned
acknowledges that the foregoing attorneys-in-fact, in serving in such capacity
at the request of the undersigned, is not assuming, nor is the Company assuming,
any of the undersigned's responsibilities to comply with Section 16 of the
Securities Exchange Act of 1934 (as amended).

        This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
Company and the foregoing attorneys-in-fact.

        IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of this 15th day of June, 2020.

                                        Signature:  /s/ Paul A. Wagner
                                                   -----------------------------

                                        Print Name:  Paul A. Wagner
                                                   -----------------------------